Microbiology of Bronchiectasis in stable state and exacerbation: data from the EMBARC bronchiectasis registry.

<bold>Introduction:</bold> This analysis describes pathogens identified at stable state and exacerbation in patients in the EMBARC bronchiectasis registry. <bold>Methods:</bold> We analysed a large cohort of patients from the European Bronchiectasis registry EMBARC (enrolled 2015-2022) with sputum samples sent at stable state and exacerbation. <bold>Results:</bold> 18843 patients were included in the study. 28272 sputum samples were sent during the study period, 17237 (61%) at stable state and 11035 (39%) at exacerbation. The most common pathogens identified across all patients were Pseudomonas aeruginosa (3175, 16.8%) Haemophilus Influenzae (2775, 14.7%), Staphylococcus aureus (1024, 5.4%) and Streptococcus pneumoniae (799, 4.2%). The most common pathogens identified at stable state and exacerbation were similar: P. aeruginosa (stable, 2032, 10.8% vs exacerbations, 1602, 8.5%), H. Influenzae (stable, 1675, 8.9% vs exacerbations, 1332, 7.1%), Enterobacteriaceae (stable, 765, 4.0% vs exacerbation, 614, 3.2%) S. aureus (stable, 661, 3.5% vs exacerbation 414, 2.2%) and S. pneumoniae (stable, 517, 2.7% vs exacerbation 514, 2.7%). There was no clear difference in pathogen distribution by aetiology, except for a higher rate of most pathogens in patients with Primary Ciliary Dyskinesia (PCD). 880 (4.7%) of patients had at least one sample growing multiple organisms. In total 1181 (4.2%) of samples grew multiple organisms. <bold>Discussion:</bold> There is no clear difference between microbiology at stable state and exacerbation and no clear variation by aetiology, except in the case of PCD which has a higher rate of most pathogens. Samples growing multiple organisms are common.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa2378
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbiology of Bronchiectasis in stable state and exacerbation: data from the EMBARC bronchiectasis registry.

Adam T. Hill, Francesco Blasi, Josje Altenburg, Michal Shteinberg et al.
Cystic Fibrosis Research Advances
article

Microbiology of Bronchiectasis in stable state and exacerbation: data from the EMBARC bronchiectasis registry.

Adam T. Hill, Francesco Blasi, Josje Altenburg, Michal Shteinberg, Fiona Mosgrove, Michael R. Loebinger, J.S. Elborn, Felix C. Ringshausen, Eva Polverino, Katerina Dimakou, Rosario Menéndez, Pieter Goeminne, James Duncan Chalmers, Tobias Welte, Montserrat Vendrell, Anthony De Soyza, Pierre‐Régis Burgel, Stefano Aliberti, Megan Crichton, Marlène Murris, Robert Wilson, Wim Boersma, Antoni Torres, Charles S Hayworth
article en

Abstract

<bold>Introduction:</bold> This analysis describes pathogens identified at stable state and exacerbation in patients in the EMBARC bronchiectasis registry. <bold>Methods:</bold> We analysed a large cohort of patients from the European Bronchiectasis registry EMBARC (enrolled 2015-2022) with sputum samples sent at stable state and exacerbation. <bold>Results:</bold> 18843 patients were included in the study. 28272 sputum samples were sent during the study period, 17237 (61%) at stable state and 11035 (39%) at exacerbation. The most common pathogens identified across all patients were Pseudomonas aeruginosa (3175, 16.8%) Haemophilus Influenzae (2775, 14.7%), Staphylococcus aureus (1024, 5.4%) and Streptococcus pneumoniae (799, 4.2%). The most common pathogens identified at stable state and exacerbation were similar: P. aeruginosa (stable, 2032, 10.8% vs exacerbations, 1602, 8.5%), H. Influenzae (stable, 1675, 8.9% vs exacerbations, 1332, 7.1%), Enterobacteriaceae (stable, 765, 4.0% vs exacerbation, 614, 3.2%) S. aureus (stable, 661, 3.5% vs exacerbation 414, 2.2%) and S. pneumoniae (stable, 517, 2.7% vs exacerbation 514, 2.7%). There was no clear difference in pathogen distribution by aetiology, except for a higher rate of most pathogens in patients with Primary Ciliary Dyskinesia (PCD). 880 (4.7%) of patients had at least one sample growing multiple organisms. In total 1181 (4.2%) of samples grew multiple organisms. <bold>Discussion:</bold> There is no clear difference between microbiology at stable state and exacerbation and no clear variation by aetiology, except in the case of PCD which has a higher rate of most pathogens. Samples growing multiple organisms are common.

Queen's University Belfast (GB), Humanitas University (IT), Inserm (FR), University of Milan (IT), University of Aberdeen (GB), Université Paris Cité (FR), Royal Papworth Hospital (GB), Ninewells Hospital (GB), Harefield Hospital (GB), Edinburgh Royal Infirmary (GB), Centre Hospitalier Universitaire de Toulouse (FR), Medizinische Hochschule Hannover (DE), Assistance Publique – Hôpitaux de Paris (FR), Northwest Hospital (US), Institut d'Investigació Biomèdica de Girona (ES), Carmel Medical Center (IL), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), NIHR Newcastle Biomedical Research Centre (GB), Institut Cochin (FR), Hospital Universitari de Girona Doctor Josep Trueta (ES), AZ Sint-Lucas (BE), Instituto de Investigación Sanitaria La Fe (ES), Sotiria General Hospital (GR), Universitat de Barcelona (ES), University of Amsterdam (NL)
Openalex Percentile: Top 63%
Cystic Fibrosis Research Advances
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.